Sodium cellulose phosphate

Sodium cellulose phosphate

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	V03AG01 (WHO)
Identifiers
ChemSpider	NA Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
(verify)

WikiDoc Resources for Sodium cellulose phosphate
Articles
Most recent articles on Sodium cellulose phosphate Most cited articles on Sodium cellulose phosphate Review articles on Sodium cellulose phosphate Articles on Sodium cellulose phosphate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sodium cellulose phosphate Images of Sodium cellulose phosphate Photos of Sodium cellulose phosphate Podcasts & MP3s on Sodium cellulose phosphate Videos on Sodium cellulose phosphate
Evidence Based Medicine
Cochrane Collaboration on Sodium cellulose phosphate Bandolier on Sodium cellulose phosphate TRIP on Sodium cellulose phosphate
Clinical Trials
Ongoing Trials on Sodium cellulose phosphate at Clinical Trials.gov Trial results on Sodium cellulose phosphate Clinical Trials on Sodium cellulose phosphate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sodium cellulose phosphate NICE Guidance on Sodium cellulose phosphate NHS PRODIGY Guidance FDA on Sodium cellulose phosphate CDC on Sodium cellulose phosphate
Books
Books on Sodium cellulose phosphate
News
Sodium cellulose phosphate in the news Be alerted to news on Sodium cellulose phosphate News trends on Sodium cellulose phosphate
Commentary
Blogs on Sodium cellulose phosphate
Definitions
Definitions of Sodium cellulose phosphate
Patient Resources / Community
Patient resources on Sodium cellulose phosphate Discussion groups on Sodium cellulose phosphate Patient Handouts on Sodium cellulose phosphate Directions to Hospitals Treating Sodium cellulose phosphate Risk calculators and risk factors for Sodium cellulose phosphate
Healthcare Provider Resources
Symptoms of Sodium cellulose phosphate Causes & Risk Factors for Sodium cellulose phosphate Diagnostic studies for Sodium cellulose phosphate Treatment of Sodium cellulose phosphate
Continuing Medical Education (CME)
CME Programs on Sodium cellulose phosphate
International
Sodium cellulose phosphate en Espanol Sodium cellulose phosphate en Francais
Business
Sodium cellulose phosphate in the Marketplace Patents on Sodium cellulose phosphate
Experimental / Informatics
List of terms related to Sodium cellulose phosphate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sodium cellulose phosphate is a drug used to treat hypercalcemia and hypercalciuria. It has been used to prevent kidney stones.

This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore the normal intestinal calcium absorption. When it is taken orally, it binds strongly to calcium and inhibits its absorption into the blood. From there, inhibition is caused due to the lower intraluminal calcium levels, which is typically available for absorption.

The mechanism of action of the drug compound can cause a couple of internal effects. Due to the binding activity of the compound with calcium, it will also bind with magnesium and cause a depletion in the body. Working off of this effect, sodium cellulose phosphate will bind with divalent intestinal cations. Because of this binding, more oxalate is available in the blood. This high level of oxalate within the intestine can also be a source of renal stones.

Studies

In the late 1970s and early 1980s, physiological action studies took place to show how intestinal calcium was absorbed and how it affects other functions within the body. By a study done at the University of Texas, it was found that sodium cellulose phosphate inhibited calcium absorption through three separate techniques.

• Calcium balance studies
• External counting method
• Formal kinetic analysis

Through these studies, major conclusions were made regarding the drug compound. Sodium cellulose phosphate reduces the renal excretion of magnesium and calcium. Phosphate and oxalate were both increased in the urine, one due to intestinal hydrolysis and the other to a reduced oxalate complex. Overall, it was noted that the drug could be used to correct the increased calcium absorption that occurs in absorptive hypercalciuria.

Calcibind

The major US dosage form of sodium cellulose phosphate is Calcibind, which was developed and brought to market by Mission Pharma. Calcibind is a powder dosage form, which comes in small, 2.5 gram doses, individually packaged. The patent for this product was approved on December 28, 1982. The product was eventually removed from the market for reasons that have not been found at this time.

Hypercalcemia

This condition occurs when there is a raised level of calcium in the blood, compared to the normal range of 2.2–2.6 mmol/L. Typical symptoms of this condition include renal stones, bone pain, abdominal discomfort, and nausea/vomiting. More severe symptoms are associated with psychiatric overtones which are consumed with anxiety, depression, and insomnia.

Hypercalciuria

Hypercalciuria occurs when there is an elevated level of calcium in the urine. This condition is due to severe calcium reabsorption within the intestines.